Corrigendum: Randomized, crossover questionnaire survey of acceptabilities of controlled-release mesalazine tablets and granules in ulcerative colitis patients

• Keiji Yagisawa,
• Taku Kobayashi,
• Ryo Ozaki,
• Shinji Okabayashi,
• Takahiko Toyonaga,
• Miki Miura,
• Mari Hayashida,
• Eiko Saito,
• Masaru Nakano,
• Hajime Matsubara,
• Tadakazu Hisamatsu,
• Toshifumi Hibi

Affiliations

Keiji Yagisawa

Department of Pharmacy and Kitasato University Kitasato Institute Hospital, Tokyo, Japan

Taku Kobayashi

Center for Advanced IBD Research and Treatment, Kitasato University Kitasato Institute Hospital, Tokyo, Japan

Ryo Ozaki

Center for Advanced IBD Research and Treatment, Kitasato University Kitasato Institute Hospital, Tokyo, Japan

Shinji Okabayashi

Center for Advanced IBD Research and Treatment, Kitasato University Kitasato Institute Hospital, Tokyo, Japan

Takahiko Toyonaga

Center for Advanced IBD Research and Treatment, Kitasato University Kitasato Institute Hospital, Tokyo, Japan

Miki Miura

The Third Department of Internal Medicine, Kyorin University School of Medicine, Tokyo, Japan

Mari Hayashida

The Third Department of Internal Medicine, Kyorin University School of Medicine, Tokyo, Japan

Eiko Saito

Center for Advanced IBD Research and Treatment, Kitasato University Kitasato Institute Hospital, Tokyo, Japan

Masaru Nakano

Center for Advanced IBD Research and Treatment, Kitasato University Kitasato Institute Hospital, Tokyo, Japan

Hajime Matsubara

Department of Pharmacy and Kitasato University Kitasato Institute Hospital, Tokyo, Japan

Tadakazu Hisamatsu

The Third Department of Internal Medicine, Kyorin University School of Medicine, Tokyo, Japan

Toshifumi Hibi

Center for Advanced IBD Research and Treatment, Kitasato University Kitasato Institute Hospital, Tokyo, Japan